Filana Therapeutics (FLNA) Operating Expenses (2010 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Filana Therapeutics was $45.97 million, down 64.7% year-over-year; for FY2025, it came in at $95.39 million, down 32.6% from FY2024.

• Annual Operating Expenses shows a five-year compound annual growth rate of 71.4% (FY2020 to FY2025).
• In prior years, Filana Therapeutics' Operating Expenses was $141.45 million in FY2024 (+33.5%), $105.96 million in FY2023 (+32.4%), $80.02 million in FY2022 (+143.5%) and $32.87 million in FY2021 (+409.9%).
• The Q2 2026 figure stands as the lowest quarterly Operating Expenses since Q2 2021.
• On a year-over-year basis, Operating Expenses has declined in each of the last five quarters, with an average decline of 26.6% over the last eight quarters.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q3 2021, with growth of 578.7%; the weakest was Q2 2026, with a decline of 79.3%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $11.17 million (Q1 2026), $13.55 million (Q4 2025) and $11.86 million (Q3 2025).